Azaindazole compounds as inhibitors of T790M containing EGFR mutants
US9951064B2 · kind B2 · utility
4Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2016 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | May 12, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.